Join the club for FREE to access the whole archive and other member benefits.

SIWA Therapeutics

Biotechnology company producing therapy that targets and destroys senescent cells.

SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells. Our current therapeutic focus is on certain rare and fast track diseases, including cancer metastasis and muscle wasting diseases, such as muscular dystrophy. Beyond these indications, senescent cells are causally implicated in a wide variety of diseases including: neurodegenerative diseases; autoimmune conditions, and infectious diseases. SIWA is currently optimizing its lead antibody, SIWA 318, and in parallel, seeking partnerships to advance SIWA 318 and other related technologies to broaden and accelerate its development pipeline.

Visit website: https://siwatherapeutics.com/

 Login to view link, or join the club to get full access to all resources and other benefits.

 Login to view link, or join the club to get full access to all resources and other benefits.

People at SIWA Therapeutics

Company Representative

CEO, CSO and Co-Founder of SIWA Therapeutics

SIWA Therapeutics News

Super summary of 3rd Annual Longevity Therapeutics Summit

Lifespan.io (LEAF) - 16-Feb-2021

More and more companies making greater and greater progress - 2021 could be an exciting year

Read more...

LMC provides background and success outlook on 14 leading senolytic companies

Longevity Marketcap - 15-Dec-2020

Comprehensive review of companies' clinical and financial state of play

Read more...

Nature Biotechnology reviews the state of play of senolytics

Nature Biotechnology - 12-Nov-2020

In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...

Read more...

LEAF interviews Lewis Gruber about targeting cancer and senescent cells

Lifespan.io (LEAF) - 11-Feb-2020

Biomarker caused by glycolysis seen in all types of cancer - exciting possibilities

Read more...